Administration reported for this specific study or labeled indication.
Context: Adults with BMI ≥27 kg/m² without diabetes
Human study regimen: Amount: 0.6, 2.4, 3.6 or 4.8 mg target arms; Route: Subcutaneous; Frequency: Once weekly; Duration: 46 weeks, including 20 weeks of escalation; Species: Human; Population: Adults with BMI ≥27 kg/m² without diabetes
Limitations: Randomized dose-finding trial. The target amounts identify study arms.
Treatment-regimen estimand mean weight change -12.2% and -13.0% versus -5.4% placebo; gastrointestinal adverse events frequent
Context: Owner-published from the Jarvis queue onto Survodutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: Sponsor-funded, 76-week follow-up, no active comparator; do not infer validation of unverified twice-weekly protocol graphics
Treatment-regimen estimand mean weight change -8.2% and -9.8% versus -3.9% placebo; HbA1c change -0.9 and -0.8 percentage points versus -0.2 placebo; GI events common
Context: Owner-published from the Jarvis queue onto Survodutide. Evidence class U (Unresolved / evidence gap). This publication does not raise that class.
Limitations: Sponsor-funded; T2D-specific population; no active comparator; efficacy estimand results must not be conflated with treatment-regimen results; not validation of unverified twice-weekly protocol graphics